A Multicenter Evaluation of Overall Susceptibility and Antimicrobial Resistance Among Streptococcus pneumoniae Isolates

Purpose: S. pneumoniae ranks as the fourth-most lethal pathogen globally in terms of fatalities associated with or attributable to resistance. In this study, Antimicrobial Testing Leadership and Surveillance (ATLAS) analysis from India aims study overall antimicrobial susceptibility (AMS) among pneumococcal isolates collected between 2018 2021. Methods: Non-duplicate clinically significant were vitro activity antibiotics was assessed against pneumoniae. Susceptibility confirmed at an International Health Management Associates (IHMA) laboratory using supplied broth microdilution panels (Omron Microscan Systems, Inc., Omron Corp., Kyoto, Japan), according Clinical Laboratory Standards Institute (CLSI) guidelines for all antibiotics. Results: Of total 86 non−duplicate Streptococcus tertiary care centers, proportion increased 8.14% (n=7) 43.02% (n=37) 2020. Most (n = 18; 48.65%) age group 31-60 years year Erythromycin revealed a decrease (71.43%) 2020 (16.22%). A decreased 90% recorded levofloxacin Meropenem (85.71%) (35.14%). Penicillin 37.5% 2019 27.03% Clindamycin indicated 100% which then 71.88% 56.76% Linezolid vancomycin found have uniform throughout Conclusion: An increase resistance penicillin macrolides observed Indian population. Addressing elevating rates may require conjugate vaccines (PCVs) expanded serotype coverage targeted stewardship efforts.